Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)

被引:4
|
作者
Woo, Henry H. [1 ,2 ,3 ]
Khanani, Hadia [2 ]
Thompson, Nadine J. [4 ]
Sorensen, Brian J. [4 ]
Baskaranathan, Sris [2 ,3 ]
Bergersen, Philip [2 ,3 ]
Chalasani, Venu [2 ,3 ]
Dean, Thomas [2 ,3 ]
Dias, Max [2 ,3 ]
Symons, James [1 ,2 ,3 ]
Wines, Michael [2 ,3 ]
Jain, Anika [2 ]
Nassour, Anthony -Joe [2 ]
Tarlinton, Lisa C. [2 ,4 ,5 ]
机构
[1] Australian Natl Univ, Coll Hlth & Med, Canberra, Australia
[2] Sydney Adventist Hosp, SAN Prostate Ctr Excellence, Sydney, NSW, Australia
[3] Sydney Adventist Hosp, Dept Urol, Sydney, NSW, Australia
[4] Sydney Adventist Hosp, SAN Radiol & Nucl Med, Sydney, NSW, Australia
[5] Sydney Adventist Hosp, SAN Radiol & Nucl Med, 185 Fox Rd, Wahroonga, NSW 2076, Australia
来源
EUROPEAN UROLOGY OPEN SCIENCE | 2023年 / 47卷
关键词
Magnetic resonance imaging; Positron emission tomography; Prostate biopsy; Prostate cancer; Prostate -specific membrane; antigen; DIAGNOSTIC CERTAINTY; LEXICON;
D O I
10.1016/j.euros.2022.11.012
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Prostate-specific membrane antigen (PSMA) positron emission tomography/computerised tomography (PET/CT) is increasingly being utilised in the diagnostic pathway for prostate cancer (PCa). Recent publications have sug-gested that this might help identify those who can avoid biopsy.Objective: The primary objective of this study was to determine whether PET mag-netic resonance imaging (MRI) fusion could negate the need to biopsy prior to prostatectomy in a selected population of men.Design, setting, and participant: Multiparametric MRI (mpMRI) for PCa is our stan-dard of care prior to prostate biopsy. Biopsy-naive men with one or more Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesions >10 mm on mpMRI were invited to undergo PSMA PET/CT prior to biopsy. Following ethics approval, 60 men were recruited between September 2020 and March 2021. The key exclusion criteria included a previous history of PCa and previous prostate sur-gery or biopsy.Outcome measurements and statistical analysis: A positive PET MRI fusion scan was defined as "consistent with"as per the Memorial Sloan Kettering Cancer Center lexicon of certainty, and concordance with biopsy results was analysed. Clinically significant PCa (csPCa) was defined as grade group (GG) >= 2 on pathology. A chi-square analysis was performed with statistical significance defined at p < 0.05.Results and limitations: A total of 71 mpMRI lesions were positive on 61 (86%) PET MRI fusion scans. Fifty-nine of 61 lesions biopsied confirmed csPCa in 54 (92%). Of five of 59 lesions for which either biopsy was negative or low-grade cancer was found, three had rebiopsy of which two were confirmed to have csPCa corroborating with PET MRI fusion and one was reconfirmed to have GG1 only. For the remaining two, both had another lesion elsewhere in the gland confirming csPCa, and hence rebiopsy was not performed. Ultimately, 56 of 59 (95%) lesions with a positive PET MRI fusion scan were confirmed to have csPCa. All GG >3 can-cers had a positive PET MRI fusion scan. Conclusions: This prospective study of PET MRI fusion assessment of men with PI-RADS 4 or 5 lesion >10 mm on mpMRI confirms that the majority of men (95%) with a positive PET MRI fusion scan will have csPCa. This supports recently pub-lished retrospective data suggesting that selected men might avoid prostate biopsy prior to radical prostatectomy.Patient summary: In this research, we have confirmed that prostate-specific mem-brane antigen positron emission tomography/computerised tomography in combi-nation with magnetic resonance imaging could have an important role in enabling a diagnosis of prostate cancer. Using the combination of these scans, we could con-fidently predict the presence of aggressive prostate cancer in some men for which treatment is warranted. This means that there are some men who could possibility proceed directly to having prostate cancer surgery without the need for a confirma-tory prostate biopsy.(c) 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:119 / 125
页数:7
相关论文
共 50 条
  • [31] The Probability of Metastases Within Different Prostate-specific Antigen Ranges Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer
    Luining, Wietske I.
    Hagens, Marinus J.
    Meijer, Dennie
    Ringia, Joanneke B.
    de Weijer, Tessa
    Bektas, Huseyyin O.
    Ettema, Rosemarijn H.
    Knol, Remco J. J.
    Roeleveld, Ton A.
    Srbljin, Sandra
    Weltings, Saskia
    Koppes, Jose C. C.
    Moorselaar, Reindert J. A. van
    van Leeuwen, Pim J.
    Oprea-Lager, Daniela E.
    Vis, AndreN.
    EUROPEAN UROLOGY OPEN SCIENCE, 2024, 59 : 55 - 62
  • [32] Systematic Review and Metanalysis on the Role of Prostate-Specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging for Intraprostatic Tumour Assessment
    Mapelli, Paola
    Ghezzo, Samuele
    Spataro, Alessandro
    Bezzi, Carolina
    Gajate, Ana Maria Samanes
    Chiti, Arturo
    Picchio, Maria
    MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2023, 31 (04) : 605 - 611
  • [33] Comparison of Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging in Patients with Prostate Biopsy Indications
    Altay, Mehmet Sefa
    Ozkaya, Fatih
    Demirdogen, Saban Oguz
    Bedir, Fevzi
    Kocaturk, Huseyin
    Cinislioglu, Ahmet Emre
    Yilmaz, Sinan
    Yapanoglu, Turgut
    EURASIAN JOURNAL OF MEDICINE, 2022, 54 (01) : 12 - 16
  • [34] A machine learning model incorporating 18F-prostate-specific membrane antigen-1007 positron emission tomography/computed tomography and multiparametric magnetic resonance imaging for predicting prostate-specific antigen persistence in patients with prostate cancer after radical prostatectomy
    Chen, Fangansheng
    Jiang, Jia
    Peng, Yushi
    Wang, Ling
    Lan, Junping
    Bian, Shuying
    Wang, Hanzhe
    Xiao, Zhe
    Chen, Yimin
    Fu, Yinuo
    Zheng, Xiangwu
    Tang, Kun
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2025, 15 (01) : 30 - 41
  • [35] Diagnostic Performance of 68Gallium Labelled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging for Staging the Prostate Cancer with Intermediate or High Risk Prior to Radical Prostatectomy: A Systematic Review and Meta-Analysis
    Wu, Hui
    Xu, Ting
    Wang, Xiao
    Yu, Yong-Bo
    Fan, Zhong-Yuan
    Li, Dan-Xia
    Luo, Lei
    Yang, Xue-Cheng
    Jiao, Wei
    Niu, Hai-Tao
    WORLD JOURNAL OF MENS HEALTH, 2020, 38 (02) : 208 - 219
  • [36] Clinical Translation of Positive Metastases Identified on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging in the Management of De Novo Synchronous Oligometastatic Prostate Cancer
    Connor, Martin J.
    Dubash, Suraiya
    Bass, Edward J.
    Tam, Henry
    Barwick, Tara
    Khoo, Vincent
    Winkler, Mathias
    Ahmed, Hashim U.
    EUROPEAN UROLOGY FOCUS, 2021, 7 (05): : 951 - 954
  • [37] Evaluating Texture-Based Prostate Cancer Classification on Multi-Parametric Magnetic Resonance Imaging and Prostate Specific Membrane Antigen Positron Emission Tomography
    Alfano, R.
    Bauman, G. S.
    Thiessen, J.
    Rachinsky, I.
    Pavlovsky, W.
    Butler, J.
    Gaed, M.
    Moussa, M.
    Gomez, J. A.
    Chin, J. L.
    Pautler, S.
    Ward, A. D.
    MEDICAL IMAGING 2020: COMPUTER-AIDED DIAGNOSIS, 2020, 11314
  • [38] Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy
    Paddubny, Kiryl
    Freitag, Martin T.
    Kratochwil, Clemens
    Koerber, Stefan
    Radtke, Jan P.
    Sakovich, Ruslan
    Kopka, Klaus
    Giesel, Frederik L.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 103 - 105
  • [39] Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging
    Meijer, Dennie
    van Leeuwen, Pim J.
    Donswijk, Maarten L.
    Boellaard, Thierry N.
    Schoots, Ivo G.
    van der Poel, Henk G.
    Hendrikse, Harry N.
    Oprea-Lager, Daniela E.
    Vis, Andre N.
    BJU INTERNATIONAL, 2022, 129 (01) : 54 - 62
  • [40] Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer
    Doan, Paul
    Counter, William
    Papa, Nathan
    Sheehan-Dare, Gemma
    Ho, Bao
    Lee, Jonathan
    Liu, Victor
    Thompson, James E.
    Agrawal, Shikha
    Roberts, Matthew J.
    Buteau, James
    Hofman, Michael S.
    Moon, Daniel
    Lawrentschuk, Nathan
    Murphy, Declan
    Stricker, Phillip D.
    Emmett, Louise
    BJU INTERNATIONAL, 2023, 131 (05) : 588 - 595